Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1279851 | 1.00 | MEN1 (0.44) | MEN1KMT2AALDH1A1KDM4EMAOB | |
| SCHEMBL1279588 | 1.00 | MEN1 (0.44) | MEN1KMT2AALDH1A1KDM4EMAOB | |
| SCHEMBL1279464 | 0.89 | CD274 (0.51) | MEN1KMT2AALDH1A1KDM4ECD274 | |
| SCHEMBL1279848 | 0.86 | CD274 (0.43) | MEN1KMT2AALDH1A1CD274POLB | |
| SCHEMBL1279849 | 0.86 | CD274 (0.43) | MEN1KMT2AALDH1A1CD274POLB | |
| SCHEMBL1279277 | 0.84 | POLB (0.41) | MEN1KMT2AALDH1A1CD274POLB | |
| SCHEMBL1279278 | 0.84 | POLB (0.41) | MEN1KMT2AALDH1A1CD274POLB | |
| SCHEMBL1278891 | 0.82 | MEP1B (0.46) | MEN1KMT2AALDH1A1KDM4ECD274 | |
| SCHEMBL12051373 | 0.82 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1CD274MEP1B | |
| SCHEMBL13536742 | 0.81 | SLC7A5 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9247759-B2 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20130345222-A1 | IDENTIFICATION OF HUMAN T2R RECEPTORS THAT RESPOND TO BITTER COMPOUNDS THAT ELICIT THE BITTER TASTE IN COMPOSITIONS, AND THE USE THEREOF IN ASSAYS TO IDENTIFY COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITIONS AND USE THEREOF | FIRMENICH INCORPORATED | 2013-12-26 | — | — | US | disclosed |
| US-8445692-B2 | Compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120088796-A1 | COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND USE THEREOF | SENOMYX, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8076491-B2 | Compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2011106114-A1 | IDENTIFICATION OF HUMAN T2R RECEPTORS AND THE USE THEREOF TO IDENTIFY INHIBITORS (BLOCKERS) OF BITTER TASTE | SENOMYX, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088796-A1 | COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND USE THEREOF | TAS2R50, TAS2R5, TAS2R1 | MEN1 2294/4885KMT2A 3406/4885ALDH1A1 2764/4885 |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | TAS2R50, TAS2R1, TAS2R30 | MEN1 2097/4885KMT2A 3181/4885ALDH1A1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.